Volume 222, Issue Supplement_1, 1 August 2020

Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators

• Abstract
• View article
• Supplementary data

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

• Abstract
• View article
• Supplementary data

Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial

• Abstract
• View article
• Supplementary data

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

• Abstract
• View article
• Supplementary data

An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus

• Abstract
• View article
• Supplementary data

Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE

• Abstract
• View article
• Supplementary data

Myocardial Steatosis Among Antiretroviral Therapy–Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial

• Abstract
• View article
• Supplementary data